PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Aumolertinib→

Aumolertinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1899921-05-1
Molecular formula
C30H35N7O2
Molecular weight
525.6 g/mol
Drug class
Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitortargeted antineoplastic
Mechanism of action
Selectively and irreversibly inhibits mutant EGFR, including sensitising mutations and T790M resistance mutation, reducing downstream oncogenic signalling in EGFR-mutated tumour cells.
Indications / reported uses
  • Treatment of locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) in China and other jurisdictions where aumolertinib is authorised; treatment line and mutation criteria are product- and jurisdiction-specific

Sources: PubMed — Aumolertinib clinical pharmacology and NSCLC · NLM MeSH — Aumolertinib · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Aumolertinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Aumolertinib Permitted Daily Exposure (PDE) report (the Aumolertinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Aumolertinib Occupational Exposure Limit (OEL) report (the Aumolertinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.